Read Time:12 Second
Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
